• Q1/21  DEXTENZA®  Umsätze 6,7 Mio. $
  

https://ocutx.gcs-web.com/news-releases/...rst-quarter-2021-financial

 

Zahlen für Q2/21

• DEXTENZA-Umsätze 11,7 Mio. $
  
• oper. Verlust 20 Mio. $
  
• Cash 192 Mio. $ ("through 2023")
  
• MK 819 Mio. $
  

- DEXTENZA® Recorded Net Quarterly Sales of $11.1 Million, Representing Quarterly Sequential Growth of Approximately 65%

https://ocutx.gcs-web.com/news-releases/...ond-quarter-2021-financial

 

und dennoch Buy rating 30 Dollar  

FDA-Zulassung für DEXTENZA

• neue Indikation
  
• Dexamethason-Ophthalmeinlage 0,4 mg zur intrakanalikulären Anwendung zur Behandlung von Augenjucken im Zusammenhang mit allergischer Konjunktivitis
  

https://ocutx.gcs-web.com/news-releases/...pproval-supplemental-new-0

 

https://www.benzinga.com/news/21/10/23330091/...es-price-target-to-18  

https://ocutx.gcs-web.com/static-files/...ebaf-44ed-a6c5-b43099f6fb50

Sehr interessante Pipeline

3 FDA Approvals

Total global market >23B$  

https://ocutx.gcs-web.com/static-files/...ebaf-44ed-a6c5-b43099f6fb50

Sehr interessante Pipeline

3 FDA Approvals

Total global market >23B$  

enttäuschende Phase2 Studienergebnisse von OTX-CSI (in DED)

https://ocutx.gcs-web.com/news-releases/...e-results-phase-2-clinical

 

• MK 529 Mio. $
  

https://endpts.com/...-a-phii-failure-in-dry-eye-disease-shares-tank/
https://www.fool.com/investing/2021/10/22/...x-stock-is-sinking-toda/

 

Zahlen für Q4/ 2021

• Umsatz 12 Mio. $
  
• oper. Verlust 18 Mio. $
  
• Cash 164 Mio. $
  
• MK 336 Mio. $
  

"the Company believes that existing cash and cash equivalents, as of December 31, 2021, will enable the Company to fund planned operating expenses, debt service obligations and capital expenditure requirements through 2023 "

https://ocutx.gcs-web.com/news-releases/...-quarter-and-year-end-2021

 

Zahlen für Q1/22

• Umsatz 13 Mio. $
  
• oper. Verlust 18 Mio. $
  
• Cash 145 Mio. $
  
• MK 250 Mio. $
  

-  Guiding DEXTENZA Annual Net Product Revenue for 2022 between $55 to $60 million

-  Topline Data from the U.S.-based Clinical Trial for OTX-TKI for the Treatment of Wet AMD Anticipated in the Third Quarter of 2022

https://ocutx.gcs-web.com/news-releases/...rst-quarter-2022-financial

 

Zahlen für Q2/22

• Umsatz 12,3 Mio. $
  
• Verlust 18,8 Mio. $
  
• Cash 135 Mio. $
  
• MK 418 Mio. $
  

- Interim Data from the U.S.-based Clinical Trial for OTX-TKI for the Treatment of Wet AMD to be Presented at American Academy of Ophthalmology (AAO) in the Third Quarter of 2022

https://ocutx.gcs-web.com/news-releases/...ond-quarter-2022-financial

 

Zahlen für Q3/22

• Umsatz 12 Mio. $
  
• Verlust 24 Mio. $
  
• Cash 121 Mio. $
  
• MK 222 Mio. $
  

https://ocutx.gcs-web.com/news-releases/...ird-quarter-2022-financial

 

VORLÄUFIGE 10-MONATSDATEN AUS DER PHASE-1-STUDIE DER USA ZUR BEWERTUNG VON OTX-TKI (wAMD)

https://ocutx.gcs-web.com/news-releases/...m-10-month-data-ongoing-us

 

"Ocular Therapeutix: Q1 Earnings Snapshot
05/08/2023 | 05:08pm EDT
BEDFORD, Mass. (AP) — BEDFORD, Mass. (AP) — Ocular Therapeutix Inc. (OCUL) on Monday reported a loss of $30.3 million in its first quarter.

On a per-share basis, the Bedford, Massachusetts-based company said it had a loss of 39 cents. Losses, adjusted for non-recurring costs, came to 31 cents per share.

The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 27 cents per share.

The biotechnology company posted revenue of $13.4 million in the period, which also missed Street forecasts. Four analysts surveyed by Zacks expected $14 million."
https://www.marketscreener.com/quote/stock/...ings-Snapshot-43781085/

Mal weiter beobachten;

 

12-Monats-Topline-Daten aus der  Phase-1-Studie in den USA zur Bewertung von OTX-TKI (wAMD)

https://ocutx.gcs-web.com/news-releases/...th-topline-data-ongoing-us

 

So schlecht waren die Daten gar nicht.
 

Zahlen für Q1/23

• Umsatz 13,4 Mio. $
  
• oper. Verlust 23 Mio. $
  
• Cash 79 Mio. $
  
• MK 435 Mio. $
  

https://ocutx.gcs-web.com/news-releases/...rst-quarter-2023-financial

OCUL sieht sich bis Mitte 2024 finanziert

 

Zwar ist die MK auf rund 340 Mio. $ gesunken, aber dennoch sind hier einige Fragen (der Finanzierung) offen. Manche hoffen auf eine Übernahme, andere befürchten ein verwässerendes Offering.  

Zahlen für Q2/23

• Umsatz 15 Mio. $
  
• Verlust 21 Mio. $
  
• Cash 67 Mio. $
  
• MK 309 Mio. $
  

- Closed on a New $82.5 million Credit Facility

https://investors.ocutx.com/news-releases/...d-quarter-2023-financial

 

MK 196 Mio. $, die Bewertung ist ein Stück zurückgekommen. Aktuell ist OCUL mit dem 3,3fachen seines Jahresumsatzes bewertet.  

Zahlen für Q3/23

• Umsatz 15 Mio. $
  
• operativer Verlust 19 Mio. $
  
• Cash 111 Mio. $
  
• MK 196 Mio. $
  

- Top-line Data from U.S.-based HELIOS Trial Evaluating AXPAXLI for Treatment of Non-Proliferative Diabetic Retinopathy Anticipated to be Presented in in Q2 2024

- Top-line Data from U.S.-based Phase 2 Clinical Trial of OTX-TIC for Treatment of Primary Open-Angle Glaucoma or Ocular Hypertension Anticipated to be Presented at ASCRS Meeting in Early April 2024 

https://investors.ocutx.com/news-releases/...d-quarter-2023-financial

 

https://investors.ocutx.com/news-releases/...ubjects-screened-phase-3
Verdreifacht seit November.